Website intended for a NZ health professional readership
Psychiatrist David Codyre reviews the growing evidence for low-dose naltrexone in the treatment of functional syndromes such as fibromyalgia, chronic fatigue and long COVID
1. Toljan K, Vrooman B. Low-dose naltrexone (LDN) – review of therapeutic utilization. Med Sci (Basel) 2018;6(4):82.
2. Hatfield E, Phillips K, Swidan S, et al Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc 2020;151(12):891–902.e1.
3. Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16(1):55.
4. O’Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 2022;24:100485.
Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment
